Evidence map›Paper›PMID 37168417›Full record

ArticleInternational journal of cardiology. Heart & vasculature2023

Contemporary trends and barriers to oral anticoagulation therapy in Non-valvular atrial fibrillation during DOAC predominant era.

Ojasav Sehrawat, Anthony H Kashou, Holly K Van Houten, Ken Cohen, Henry Joe Henk, Bernard J Gersh, Neena S Abraham, Jonathan Graff-Radford, Paul A Friedman, Konstantinos C Siontis and 2 more

Abstract read
In one paragraph

Article in International journal of cardiology. Heart & vasculature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Recent highlights from theInternational journal of cardiology. Heart & vasculature · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Protease-activated receptor 2 at the intersection of thrombo-inflammation and beyond.International journal of cardiology. Heart & vasculature · 2024
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ojasav SehrawatDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United States.
Anthony H KashouDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United States.
Holly K Van HoutenRobert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, United States.
Ken CohenOptum Center for Research and Innovation, Minnetonka, MN, United States.
Henry Joe HenkUnitedHealthcare, 9700 Health Care Lane, Minnetonka, MN 55343, USA.
Bernard J GershDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United States.
Neena S AbrahamRobert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, United States.
Jonathan Graff-RadfordDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Paul A FriedmanDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United States.
Konstantinos C SiontisDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United States.
Peter A NoseworthyDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United States.
Xiaoxi YaoDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is a need to reassess contemporary oral anticoagulation (OAC) trends and barriers against guideline directed therapy in the United States. Most previous studies were performed before major guideline changes recommended direct oral anticoagulant (DOAC) use over warfarin or have otherwise lacked patient level data. Data on overuse of OAC in low-risk group is also limited. To address these knowledge gaps, we performed a nationwide analysis to analyze current trends. This is a retrospective cohort study assessing non-valvular AF identified using a large United States de-identified administrative claims database, including commercial and Medicare Advantage enrollees. Prescription fills were assessed within a 90-day follow-up from the patient's index AF encounter between January 1, 2016, and December 31, 2020. Among the 339,197 AF patients, 4.4%, 8.0%, and 87.6% were in the low-, moderate-, and high-risk groups (according to CHA

Indexed as

Atrial fibrillationnon-vitamin K oral anticoagulantOral anticoagulantPrescriptionStrokeWarfarin

Identifiers

PMID37168417
PMCPMC10164915

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.